• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Grifols wins FDA nod for liquid formulation of replacement therapy for rare genetic disorder

September 22, 2017 By Sarah Faulkner

GrifolsGrifols (NSDQ:GRFS) said today that it won FDA approval for a liquid formulation of its alpha-1 antitrypsin, Prolastin-C Liquid, as a replacement therapy to treat alpha-1 antitrypsin deficiency.

Prior to this approval, the company only offered Prolastin-C in a lyophilized format. The new formulation requires less preparation time and volume for infusion, according to Barcelona-based Grifols.

The company touted its product as the first liquid formulation of an alpha-1 antitrypsin deficiency replacement therapy made in the U.S. Prolastin-C Liquid will also be manufactured in Spain, Grifols reported in a regulatory filing.

The commercial launch for the new liquid formulation is scheduled for next year. The company is also looking to get its product approved in Europe.

Earlier this month, the European Medicine Agency’s Committee for Medicinal Products for Human Use recommended approval for Grifol’s VeraSeal product.

The biological sealant, made up of fibrinogen and human thrombin, is designed to accelerate the healing process following surgical operations in adults.

GRFS shares were trading at $20.90 apiece in mid-morning activity today, up 0.7%.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Surgical, Wall Street Beat Tagged With: Grifols

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS